David Salas Gómez, PhD
About David Salas Gómez, PhD
David Salas Gómez, PhD, is a scientist specializing in gene therapy and translational research. He has worked at Viralgen Vector Core and Asklepios BioPharmaceutical, Inc., and previously held a position at Universidad de Navarra for 14 years.
Work at Asklepios BioPharmaceutical
David Salas Gómez, PhD, has been employed at Asklepios BioPharmaceutical, Inc. (AskBio) since 2021. In his role as a Scientist, he focuses on advancing research initiatives related to gene therapy. His work contributes to the development of innovative therapeutic solutions that utilize adeno-associated virus (AAV) vectors. This position aligns with his extensive background in translational research, emphasizing the application of laboratory discoveries in clinical settings.
Current Role at Viralgen Vector Core
Since 2021, David Salas Gómez has been working at Viralgen Vector Core in Donostia-San Sebastián, País Vasco / Euskadi, España, as part of the translational research team. His responsibilities include the development and optimization of viral vector systems for gene therapy applications. His expertise in recombinant adeno-associated virus (rAAV) vectors plays a crucial role in the advancement of therapeutic strategies aimed at treating genetic disorders.
Previous Experience at Universidad de Navarra
David Salas Gómez worked at Universidad de Navarra as a Biotecnologo from 2007 to 2021, accumulating 14 years of experience in the academic sector. During his tenure, he contributed to various research projects, focusing on biotechnology and gene therapy. His work at the university laid the foundation for his subsequent roles in the field and enhanced his expertise in the development of gene therapy techniques.
Education and Expertise
David Salas Gómez holds a Doctorate in Ciencias biomédicas from Universidad de Navarra, which he completed between 2014 and 2019. He also achieved a Licenciado in Bioquímica from the same institution in 2007. Additionally, he pursued a Master of Business Administration (MBA) at CESIF from 2020 to 2021. His educational background equips him with a strong foundation in both scientific research and business management, enhancing his capabilities in translational research.
Contributions to Gene Therapy
David Salas Gómez has made significant contributions to the field of gene therapy, particularly through his work with recombinant adeno-associated virus (rAAV) vectors. His expertise in the development and application of gene therapy techniques has been instrumental in bridging laboratory research with clinical applications. His focus on translational research aims to facilitate the practical implementation of scientific discoveries in therapeutic contexts.